SCN1A and epilepsy: The first-line drug-based therapy for SCN1A epilepsy diseases is the enhancement of postsynaptic GABAergic transmission with allosteric activation of GABAA receptors as target by Clobazam and/or an increase in GABA concentration in synaptic cleft resulting from increased GABA production and decreased GABA degradation as target by Valproic acid (Catterall, 2014a; Hammer et al., 2016; Knupp and Wirrell, 2018; Musto et al., 2020).